Financial Performance - In 2023, the company's operating revenue was RMB 215,101,819.65, a decrease of 18.65% compared to RMB 264,415,476.77 in 2022[25]. - The net profit attributable to shareholders was RMB 84,755,693.84, down 24.78% from RMB 112,680,976.01 in the previous year[25]. - The gross profit margin for 2023 was 52.67%, slightly up from 52.47% in 2022[25]. - The basic earnings per share decreased by 25.00% to 1.41 from 1.88 in 2022[25]. - The weighted average return on equity was 32.45%, down from 46.77% in 2022[25]. - Operating cash flow decreased by 38.35% to ¥59,881,421.65 compared to 2022[27]. - The company's cash and cash equivalents decreased by 27.91% to ¥101.38 million, down from ¥140.63 million at the end of 2022[46]. - The accounts receivable turnover rate decreased to 8.12 from 15.40 in the previous year[28]. - The company's operating costs for 2023 were approximately ¥101.82 million, a decrease of 18.99% from ¥125.69 million in 2022[52]. - The company experienced a 40.91% reduction in financial expenses, which amounted to -¥4.73 million in 2023 compared to -¥8.01 million in 2022[52]. Capital and Investments - The company successfully raised RMB 398,000,000.00 through the issuance of 20 million shares at a price of RMB 19.90 each[21]. - After the capital increase, the company's registered capital is now RMB 80,000,000.00[21]. - Total assets increased by 6.03% to ¥307,375,267.23 compared to the end of 2022[27]. - Total liabilities decreased by 27.96% to ¥22,982,422.60 compared to the end of 2022[27]. - The company has committed to continuous innovation and market adaptation to prevent overcapacity and underperformance in fundraising projects[91]. Research and Development - R&D expenditure amounted to ¥9,034,133.57, representing 4.20% of operating revenue, up from 3.62% in the previous year[68]. - The company has six patents, all of which are invention patents, an increase from three in the previous year[69]. - The company invested a total of ¥6,600,000 in R&D during the reporting period, focusing on optimizing existing raw materials and developing new products[178]. - The top five R&D projects include the synthesis of DX raw materials with an investment of ¥600,828.28, XP raw materials with ¥1,139,958.60, and SMM raw materials with ¥2,441,638.58, all currently in the pilot stage[180]. - The company has achieved breakthroughs in the synthesis processes of SMM and SDM raw materials, significantly improving quality, yield, and cost[178]. Market and Industry Outlook - The domestic veterinary drug market is projected to reach ¥1,395.72 billion by 2027, with a compound annual growth rate of 12.56%[44]. - The veterinary drug industry is experiencing a growth phase due to the shift towards intensive farming practices, increasing the demand for veterinary pharmaceuticals[168]. - The global population is projected to reach 8.5 billion by 2030, with an increasing demand for pharmaceuticals driven by an aging population, thereby expanding the market for raw materials[170]. - The company is positioned to benefit from national policies promoting the green development of the pharmaceutical industry, which supports high-quality growth[166]. Environmental and Social Responsibility - The company has implemented a comprehensive wastewater treatment system, ensuring compliance with the "Comprehensive Wastewater Discharge Standard" (GB8978-1996) and other relevant regulations[75]. - The company has established online monitoring systems for wastewater discharge, tracking key indicators such as flow rate, pH, COD, and ammonia nitrogen[75]. - The company maintains a strong commitment to corporate social responsibility, including environmental protection and employee welfare[74]. - The company adheres to the "resource utilization, reduction, and harmlessness" principle for solid waste management, with hazardous waste being disposed of by qualified professional institutions[79]. Corporate Governance and Compliance - The company has established a governance structure that includes a board of directors with two independent directors, ensuring compliance with legal requirements[190]. - The company has implemented a system to ensure all shareholders can exercise their rights equally and has provided online voting options for shareholder meetings[191]. - The company has established a responsibility accountability system for significant errors in annual reports[189]. - The company has complied with all legal regulations regarding hazardous chemicals and has established relevant systems and facilities[186]. Shareholder and Stock Management - The company has ongoing commitments related to share lock-up and reduction, with a commitment period of 12 months from the public offering date[98]. - If the stock price falls below the offering price for 20 consecutive trading days, the lock-up period will be extended by 6 months[99]. - The company has committed to ensuring that any share reductions after the lock-up period will not be below the offering price[101]. - The company has approved a stock price stabilization plan, which includes measures such as share buybacks and increases by major shareholders if certain conditions are met[104]. Risk Management - The company is facing increased production costs due to stricter environmental regulations, which may lead to the elimination of non-compliant enterprises in the industry[87]. - The company is actively seeking strong partners to develop its generic drug business, aiming to enrich its existing product structure[86]. - The company has established a warning mechanism for raw material price changes to manage the risk of rising costs affecting profitability[90]. - Approximately 50% of the company's exports are subject to foreign exchange rate fluctuations, which may lead to potential exchange losses as the company expands overseas[88].

Financial Performance - Net profit attributable to shareholders decreased by 20.81% to ¥16,766,047.65 for the first quarter of 2024 [12]. - Operating revenue for the first quarter of 2024 was ¥41,910,557.19, a decrease of 27.50% year-on-year [12]. - Total operating revenue for Q1 2024 was CNY 41,910,557.19, a decrease from CNY 57,808,751.06 in Q1 2023, representing a decline of approximately 27.5% [30]. - Net profit for Q1 2024 was CNY 16,766,047.65, compared to CNY 21,172,619.70 in Q1 2023, reflecting a decrease of approximately 20.9% [31]. - Basic and diluted earnings per share for Q1 2024 were both CNY 0.21, down from CNY 0.35 in Q1 2023 [32]. - Total operating costs for Q1 2024 were CNY 22,625,437.43, down from CNY 32,709,750.84 in Q1 2023, indicating a reduction of about 30.8% [30]. - Research and development expenses for Q1 2024 were CNY 1,954,621.71, down from CNY 2,443,522.94 in Q1 2023, indicating a decrease of about 20% [30]. Assets and Liabilities - Total assets increased by 120.20% to ¥676,846,394.12 compared to the end of last year [12]. - The company reported a total of 529,409,707.17 CNY in current assets as of March 31, 2024, compared to 178,234,543.26 CNY at the end of 2023, indicating a significant increase [28]. - Total liabilities decreased to CNY 19,038,102.45 in 2024 from CNY 22,982,422.60 in 2023, a reduction of about 17.5% [30]. - The company's total liabilities to assets ratio remained low at 2.81% [12]. - Shareholders' equity rose significantly to CNY 657,808,291.67 in 2024 from CNY 284,392,844.63 in 2023, an increase of approximately 131.5% [30]. Cash Flow - Cash flow from operating activities decreased by 67.06% to ¥4,427,962.93 compared to the same period last year [12]. - Operating cash flow for Q1 2024 was ¥4,427,962.93, a decrease of 67.9% compared to ¥13,442,875.98 in Q1 2023 [33]. - Total cash inflow from operating activities was ¥32,511,620.00, down 27.8% from ¥44,962,256.35 in the same period last year [33]. - Cash inflow from other operating activities increased to ¥2,150,574.17, up 194.3% from ¥732,813.37 in Q1 2023 [33]. - Cash and cash equivalents increased by 348.50% to ¥454,706,743.51 due to fundraising [13]. - The cash and cash equivalents at the end of Q1 2024 totaled ¥454,706,743.51, significantly up from ¥140,091,972.99 at the end of Q1 2023 [34]. - Cash outflow from operating activities decreased to ¥28,083,657.07, a reduction of 10.3% compared to ¥31,519,380.37 in Q1 2023 [33]. - Investment activities resulted in a net cash outflow of ¥10,322,508.33, compared to a net outflow of ¥2,531,664.83 in Q1 2023 [34]. - Cash inflow from financing activities was ¥367,150,000.00, with a net cash flow of ¥358,978,400.00 after outflows [34]. - The company experienced a positive impact of ¥240,089.75 from exchange rate fluctuations on cash and cash equivalents [34]. Shareholder Information - The number of shares increased by 33.33% to 80,000,000 due to a public offering [13]. - The top five shareholders collectively hold 80.0739% of the company's shares, with the largest shareholder owning 24.75% [21]. - The company has no shareholders with pledged or judicially frozen shares, indicating a stable ownership structure [22]. - The company has not issued any preferred shares, simplifying its capital structure [22]. Compliance and Governance - The company has not engaged in any litigation or arbitration matters during the reporting period, ensuring compliance and stability [24]. - There were no significant related party transactions or external guarantees reported, maintaining financial integrity [24]. - Non-recurring gains and losses totaled ¥146,346.95, with a net amount after tax of ¥124,394.91 [16]. - The company reported a credit impairment loss of CNY -164,580.54 in Q1 2024, compared to CNY -586,378.93 in Q1 2023, showing an improvement in credit quality [31]. Market Position - The company is actively expanding its market presence, as indicated by the increase in cash reserves and accounts receivable, positioning itself for future growth [28]. - Cash and cash equivalents increased to 454,706,743.51 CNY from 101,382,799.16 CNY, reflecting a growth of approximately 347% [28]. - Accounts receivable rose to 35,652,371.95 CNY from 31,942,433.19 CNY, representing an increase of about 59% [28]. - Sales expenses increased by 43.78% to ¥241,774.57 due to the addition of new sales personnel [14]. - Other income increased by 269.60% to ¥275,554.32, attributed to increased VAT deductions [14].

上会会计师事务所（特殊普通合伙） 中国 上海 ·计师 李 务 所（特殊善通合伙） ilied 9 ublic Accountants (Shecial Sieneral Pantnershib) 浙江海昇药业股份有限公司 浙江海昇药业股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审核报告 上会师报字(2024)第 5048 号 我们的责任是在执行审核工作的基础上对汇总表发表专项审核意见。 我们按照中国注册会计师审计准则的相关规定执行了审核工作。中国注册会计 师审计准则要求我们遵循中国注册会计师职业道德守则,计划和执行审核工作对汇 总表是否不存在重大错报获取合理保证。在审核的过程中,我们实施了包括检查会 计记录、重新计算相关项目金额等我们认为必要的程序。我们相信,我们的审核工 作为发表审核意见提供了合理的基础。 计师 李 务所（特殊善通合伙） tilied Public Accountants (Shecial Seneval Partnership) 我们认为，贵公司管理层编制的汇总表在所有重大方面符合《上市公司监管指 引第 8 号一上市公司资金往来、对外担保的监管要求》(证监会公告（20 ...

浙江海昇药业股份有限公司 审计报告 上会师报字(2024)第 5047 号 上会会计师事务所（特殊普通合伙） 中国 上海 ·计师 李今所(特殊普通台 lic Scountants (Shecial Seneval Par 审计报告 上会师报字(2024)第 5047 号 浙江海昇药业股份有限公司全体股东: 一、审计意见 我们审计了浙江海昇药业股份有限公司(以下简称"海昇药业公司")财务报表, 包括 2023 年 12 月 31 日的资产负债表, 2023 年度的利润表、现金流量表、所有者权 益变动表以及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公 允反映了海昇药业公司 2023 年 12 月 31 日的财务状况以及 2023 年度的经营成果和现 金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册 会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照 中国注册会计师职业道德守则,我们独立于海昇药业公司,并履行了职业道德方面 的其他责任。我们相信,我们获取的审计证据是充分、适当的,为发表审计意见提 ...

长江证券承销保荐有限公司 关于浙江海昇药业股份有限公司 预计 2024 年日常性关联交易的核查意见 长江证券承销保荐有限公司（以下简称"长江保荐"或"保荐机构"）为浙 江海昇药业股份有限公司（以下简称"海昇药业"或"公司"）向不特定对象公 开发行股票并在北京证券交易所（以下简称"北交所"）上市的保荐机构。根据 《北京证券交易所上市公司持续监管办法（试行）》《北京证券交易所证券发行 上市保荐业务管理细则》《北京证券交易所股票上市规则（试行）》等有关规定， 对海昇药业预计 2024 年日常性关联交易情况进行核查，具体情况如下： 一、日常性关联交易的预计情况 | | | 单位：元 | | | | --- | --- | --- | --- | --- | | | 主要交 | 预计 2024 | 2023 年关 | 预计金额与上一 | | 关联交易类别 | 易内容 | 年发生金额 | 联方实际 | 年度实际发生金 | | | | | 发生金额 | 额差异较大原因 | | 购买原材料、燃料和动力、接受劳 务 | - | - - | | | | 出售产品、商品、提供劳务 | - | - - | | | | 委托关联人销售 ...

浙江海昇药业股份有限公司 关于召开 2023 年年度股东大会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开基本情况 （一）股东大会届次 本次会议为 2023 年年度股东大会。 （二）召集人 本次股东大会的召集人为董事会。 证券代码：870656 证券简称：海昇药业 公告编号：2024-063 （三）会议召开的合法性、合规性 本次股东大会的召开符合有关法律、行政法规、部门规章、规范性文件和公 司章程，无需其他相关部门批准或履行其他程序。 （四）会议召开方式 本次会议采用现场投票和网络投票相结合方式召开。 公司同一股东只能选择现场投票、网络投票中的一种方式，如果同一表决 权出现重复投票表决，以第一次投票表决结果为准。 （五）会议召开日期和时间 1、现场会议召开时间：2024 年 5 月 20 日 14:00 时-15:00。 2、网络投票起止时间：2024 年 5 月 19 日 15:00—2024 年 5 月 20 日 15:00。 登记在册的股东可通过中国证券登记 ...

证券代码：870656 证券简称：海昇药业 公告编号：2024-052 （二）独立董事及其配偶、父母、子女未直接或间接持有公司已发行股份百 分之一以上，不是公司前十名股东中的自然人股东； （三）独立董事及其配偶、父母、子女不是直接或间接持有公司已发行股份 百分之五以上的股东，未在公司前五名股东任职； （四）独立董事及其配偶、父母、子女未在公司控股股东、实际控制人的附 属企业任职； （五）独立董事不是公司及公司控股股东、实际控制人或者其各自的附属企 业有重大业务往来的人员，未在有重大业务往来的单位及其控股股东、实际控制 人处任职； （六）独立董事不是为公司及公司控股股东、实际控制人或者其各自附属企 业提供财务、法律、咨询、保荐等服务的人员，包括但不限于提供服务的中介机 构的项目组全体人员、各级复核人员、在报告上签字的人员、合伙人、董事、高 级管理人员及主要负责人； 浙江海昇药业股份有限公司 关于董事会对 2023 年度独立董事独立性情况的专项意见 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 根据《上市 ...

浙江海昇药业股份有限公司（以下简称"公司"）聘请上会会计 师事务所（特殊普通合伙）（以下简称"上会会计师事务所"）作为 公司 2023 年年度审计机构。根据《国有企业、上市公司选聘会计师 事务所管理办法》等法律法规的要求，公司对上会会计师事务所在 2023 年度审计工作中的履职情况进行了评估，具体情况如下： 一、会计师事务所的基本情况 证券代码：870656 证券简称：海昇药业 公告编号：2024-060 浙江海昇药业股份有限公司 关于 2023 年度会计师事务所履职情况评估的报告 本公司及董事会全体成员保证公告内容的真实、准确和完整， 没有虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、 准确性和完整性承担个别及连带法律责任。 1.会计师事务所名称：上会会计师事务所（特殊普通合伙） 2.成立日期：2013 年 12 月 27 日 3.组织形式：特殊普通合伙企业 4.注册地址：上海市静安区威海路 755 号 25 层 5.基本情况：截至 2023 年末，上会会计师事务所拥有合伙人 108 名、注册会计师 506 名、签署过证券服务业务审计报告的注册会计师 179 名。2023 年经审计的收入总额、审计业 ...

浙江海昇药业股份有限公司 关于拟修订《公司章程》公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、修订内容 证券代码：870656 证券简称：海昇药业 公告编号：2024-058 除上述修订外，原《公司章程》其他条款内容保持不变，前述内容尚需提交 公司股东大会审议，具体以工商行政管理部门登记为准。 二、修订原因 根据《公司法》《证券法》《北京证券交易所股票上市规则（试行）》等相关 规定，公司拟修订《公司章程》的部分条款。同时为便于实施本次变更有关事宜， 董事会将在股东大会授权范围内，转授权公司管理层及相关部门负责办理本次变 更具体事宜，授权有效期至相关事项全部办理完毕为止。 三、备查文件 《浙江海昇药业股份有限公司第三届董事会第十五次会议决议》 浙江海昇药业股份有限公司 根据《公司法》及《证券法》《北京证券交易所股票上市规则（试行）》等相 关规定，公司拟修订《公司章程》的部分条款，修订对照如下： | 原规定 | | | | | | | | | 修订后 | | | | | --- | --- | ...

证券代码：870656 证券简称：海昇药业 公告编号：2024-050 浙江海昇药业股份有限公司 独立董事 2023 年度述职报告（王兴斌） 本公司及董事会全体成员保证公告内容的真实、准确和完整， 没有虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、 准确性和完整性承担个别及连带法律责任。 本人王兴斌，在浙江海昇药业股份有限公司（以下简称"公司"） 2023 年度任职期间，严格按照《公司法》、《证券法》、《上市公司治 理准则》、《上市公司独立董事管理办法》、《北京证券交易所股票上 市规则（试行）》等法律法规和《公司章程》的规定，认真履行职责， 充分发挥独立董事的作用，恪尽职守，勤勉尽责，维护公司利益，维护 全体股东尤其是中小股东的利益，履行了独立董事的职责，谨慎、认真、 勤勉地行使法律所赋予的权利，积极出席相关会议，对各项议案进行认 真审议，对公司重大事项发表了独立意见，充分发挥了独立董事的作用。 现就本人 2023 年度的履职情况报告如下： 一、独立董事的基本情况 王兴斌先生，1977 年 7 月出生，中国国籍，无境外永久居留权，本 科学历，会计专业，高级会计师。1998 年 8 月至 2001 年 ...